Integration of pharmacogenomics and theranostics with nanotechnology as quality by design (QbD) approach for formulation development of novel dosage forms for effective drug therapy-Reference-Cited by-同舟云学术

Integration of pharmacogenomics and theranostics with nanotechnology as quality by design (QbD) approach for formulation development of novel dosage forms for effective drug therapy

Published:2020-11 Issue: Volume:327 Page:500-511
ISSN:0168-3659
Container-title:Journal of Controlled Release
language:en
Short-container-title:Journal of Controlled Release

Author:

Jhawat Vikas^ORCID,Gulia Monika,Gupta Sumeet,Maddiboyina Balaji,Dutt Rohit

Publisher

Elsevier BV

Subject

Pharmaceutical Science

Reference130 articles.

1. Slowing evolution is more effective than enhancing drug development for managing resistance;McClure,2013

2. Impact of technology on the emergence of infectious diseases;Breiman;Epidemiol. Rev.,1996

3. Clinical Development Success Rates 2006-2015,2016

4. Changing R&D models in research-based pharmaceutical companies;Schuhmacher;J. Transl. Med.,2016

5. Population biological principles of drug-resistance evolution in infectious diseases;Zur Wiesch;Lancet Infect. Dis.,2011

Cited by 16 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Optimizing Process Parameters for Controlled Drug Delivery: A Quality by Design (QbD) Approach in Naltrexone Microspheres;AAPS PharmSciTech;2024-05-09

2. Electroanalysis in Pharmacogenomic Studies: Mechanisms of Drug Interaction with DNA;Biochemistry (Moscow);2024-01

3. Quality by Design in Relation to Clinical Trials;Introduction to Quality by Design (QbD);2024

4. Quality By Design in Quality Assurance;Introduction to Quality by Design (QbD);2024

5. Pharmacogenetics and pharmacogenomics;Biochemical and Molecular Pharmacology in Drug Discovery;2024